Clinical trial
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Multiple-Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MAR002 in Participants With Acromegaly (TROUGH-2)
NCT07641179 is registered in ClinicalTrials.gov with Marea Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Multiple-Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MAR002 in Participants With Acromegaly (TROUGH-2)
- Lead sponsor
- Marea Therapeutics
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- July 23, 2026
- Completion date
- December 31, 2027
- Enrollment
- 72 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.